

# Low sialic EPO ameliorate glucose homeostasis and protects embryonic development in diabetic pregnant rats.

Authors: Carlos L Pérez, Sonia Clapes, Tammy Fernández, Ninive Nuñez, Victor Rodriguez and Gipsis Suares.


> Instituto de Ciencias Básicas y Preclínicas Victoria de Girón, Universidad de Ciencias Médicas de La Habana.

#### Introduction


Erythropoietin (EPO) is a cytokine that has been know to regulate survival and development of erythroid progenitors cells (1–3). Recently, EPO has been found to regulate survival and cyto-protection of different cells types (4,5) and ameliorate glucose homeostasis (6). The aim of this study was to evaluate the effect of low sialic EPO (IsEPO) in embryonic development and glucose homeostasis in diabetic pregnant rats.

#### Materials and Methods

Female rats were injected with Sthreptozotocin (60 mg/Kg B.W.) to induce diabetes. Two weeks after diabetes diagnosis, rats were paired with healthy males. Once the pregnancy was diagnosed rats were injected with IsEPO or placebo on days 0, 2, 4, 6, 8 and 10 of pregnancy. Healthy pregnant female rats were used as negative control. Pregnancy was interrupted at day 12 to evaluate the product.




#### Results



The Glycaemia was lower in diabetic rats treated with IsEPO than in those treated with placebo. The decrease was detected as early as day 6 of treatment and was higher at day 12

#### Effect of EPO in embryo development



Diabetic rats treated with placebo show a significant increase of reabsorption and early pregnancy loss. On the other hand, diabetic rats treated with IsEPO show a decrease of reabsorption and early pregnancy loss

### Conclusions

In conclusion, these results show that IsEPO ameliorate glucose homeostasis in diabetic pregnant rats and it is the first report of the protective effect of IsEPO on embryonic development in diabetic pregnant rats.

## References

- Dolznig H, Habermann B, Stangl K, Deiner EM, Moriggl R, Beug H, et al. Apoptosis protection by the Epo target Bcl-X(L) allows factor-independent differentiation of primary erythroblasts. Curr Biol. 2002;12(13):1076–85.
- 2. Mulcahy L. The erythropoietin receptor. Semin Oncol [Internet]. 2001 Apr;28, Supple:19-23.
- Watowich SS. The Erythropoietin Receptor: Molecular Structure and Hematopoietic Signaling Pathways. J Investig Med [Internet]. 2011:59(7).
- Nangaku M. Tissue protection by erythropoietin: new findings in a moving field. Kidney Int [Internet]. International Society of Nephrology; 2013 Sep;84(3):427–9.
- Schmeding M, Boas-Knoop S, Lippert S, Ruehl M, Somasundaram R, Dagdelen T, et al. Erythropoietin promotes hepatic regeneration after extended liver resection in rats. J Gastroenterol Hepatol [Internet]. Blackwell Publishing Asia; 2008 Jul 1;23(7pt1):1125–31.
- Wang L, Di L, Noguchi CT. Erythropoietin, a Novel Versatile Player Regulating Energy Metabolism beyond the Erythroid System. Int J Biol Sci. 2014;10(8):921–39.